Evolution of the Average Target: IDEXX Laboratories, Inc.

Evolution of the Target Price: IDEXX Laboratories, Inc.

Changes in Analyst Recommendations: IDEXX Laboratories, Inc.

326ec1cfa253282561619c7ee97a4.nOoMOC71JLbop3TGhHLUKAp57j9jytJZEdakxWcRccg.85hcSnmzc-mY3xL-8QSQTW4SngwTjIRsR53t_AlGFa_ex1ZrdptnwIaTNQ~2fde2d5daab73ab6fedaeb1e990663b3
05-06 Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $665 From $655 MT
05-06 Jefferies Adjusts Price Target on IDEXX Laboratories to $792 From $785 MT
04-28 UBS Adjusts Price Target on IDEXX Laboratories to $640 From $730, Maintains Neutral Rating MT
04-27 Jefferies Adjusts Price Target on IDEXX Laboratories to $785 From $820, Maintains Buy Rating MT
04-15 Citigroup Initiates IDEXX Laboratories at Neutral With $650 Price Target MT
04-14 Leerink Partners Adjusts IDEXX Laboratories PT to $725 From $760, Maintains Outperform Rating MT
03-31 Stifel Nicolaus Adjusts IDEXX Laboratories PT to $675 From $775, Maintains Buy Rating MT
02-09 Piper Sandler Adjusts Price Target on IDEXX Laboratories to $750 From $775, Maintains Neutral Rating MT
02-05 Barclays Adjusts Price Target on IDEXX Laboratories to $800 From $850, Maintains Overweight Rating MT
02-04 Barclays Lowers Price Target on IDEXX Laboratories to $800 From $850 MT
02-03 Jefferies Adjusts Price Target on IDEXX Laboratories to $820 From $830 MT
02-03 UBS Adjusts IDEXX Laboratories PT to $730 From $750 MT
02-03 Leerink Partners Adjusts Price Target on IDEXX Laboratories to $760 From $785 MT
02-03 BTIG Adjusts Price Target on IDEXX Laboratories to $800 From $830 MT
02-03 Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $655 From $700 MT
12-09 Barclays Initiates IDEXX Laboratories With Overweight Rating, $850 Price Target MT
11-10 Piper Sandler Adjusts Price Target on IDEXX Laboratories to $775 From $700 MT
11-04 UBS Adjusts Price Target on IDEXX Laboratories to $750 From $710, Maintains Neutral Rating MT
11-04 Jefferies Adjusts Price Target on IDEXX Laboratories to $830 From $785, Maintains Buy Rating MT
11-04 Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $805 From $765, Maintains Overweight Rating MT
11-04 JPMorgan Adjusts Price Target on IDEXX Laboratories to $775 From $675, Maintains Overweight Rating MT
11-04 BTIG Adjusts Price Target on IDEXX Laboratories to $830 From $785, Maintains Buy Rating MT
11-04 BNP Paribas Exane Adjusts Price Target on IDEXX Laboratories to $823 From $761, Maintains Outperform Rating MT
11-04 Rothschild & Co Redburn Adjusts PT on IDEXX Laboratories to $700 From $670, Maintains Neutral Rating MT
11-04 Stifel Adjusts Price Target on IDEXX Laboratories to $775 From $700, Maintains Buy Rating MT

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
562.09USD
Average target price
709.14USD
Spread / Average Target
+26.16%
High Price Target
805.00USD
Spread / Highest target
+43.22%
Low Price Target
470.00USD
Spread / Lowest Target
-16.38%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Rothschild & Co Redburn
Jefferies & Co.
UBS
Citigroup
Leerink Partners
Stifel Nicolaus
Piper Sandler
Barclays
BTIG
Morgan Stanley
JPMorgan Chase
BNP Paribas Exane
BofA Securities
Redburn Atlantic
Goldman Sachs
Atlantic Equities
Credit Suisse
Guggenheim
J.P. Morgan Chase
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
562.09USD
Average target price
709.14USD
Spread / Average Target
+26.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IDXX Stock
  4. Consensus IDEXX Laboratories, Inc.
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!